Efficacy News and Research

RSS
MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010

MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010

Clinical development of RG7128 is on track: Pharmasset

Clinical development of RG7128 is on track: Pharmasset

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Cardiovascular specialists demonstrate effectiveness of using stents to repair aortas

Cardiovascular specialists demonstrate effectiveness of using stents to repair aortas

Researchers explore role of ECoG measurement to improve brain mapping technology

Researchers explore role of ECoG measurement to improve brain mapping technology

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

Conservative therapies need to be recommended over routine use of OTC cough/cold products in children

Conservative therapies need to be recommended over routine use of OTC cough/cold products in children

Natural plant extract could help treat COPD and inflammatory disorders

Natural plant extract could help treat COPD and inflammatory disorders

Researchers evaluate efficacy of GKRS in patients with pituitary adenoma

Researchers evaluate efficacy of GKRS in patients with pituitary adenoma

Hologic commences enrollment in European trial of Gestiva for prevention of recurrent preterm birth

Hologic commences enrollment in European trial of Gestiva for prevention of recurrent preterm birth

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Stratatech to advance living human skin substitute tissue clinical trial with $3M funding round

Stratatech to advance living human skin substitute tissue clinical trial with $3M funding round

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.